Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655557 | 0.89 | KMO (0.48) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL19023119 | 0.84 | SYK (0.56) | SYKKDM4EHSD17B10KMOMAOA | |
| SCHEMBL14564354 | 0.84 | SYK (0.48) | SYKKDM4EHSD17B10KMOMAPT | |
| SCHEMBL15447289 | 0.83 | SYK (0.48) | SYKKDM4EHSD17B10KMOMAOA | |
| SCHEMBL13727580 | 0.83 | CHEK1 (0.54) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL27730024 | 0.81 | CHEK1 (0.56) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL26356567 | 0.81 | CHEK1 (0.54) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL4300707 | 0.80 | NPC1 (0.56) | KDM4EHSD17B10KMONPC1RAB9A | |
| SCHEMBL655729 | 0.79 | GLS (0.60) | SYKKDM4EHSD17B10MAPTNPC1 | |
| SCHEMBL24150166 | 0.79 | IRAK4 (0.49) | SYKKDM4EKMOSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| EP-1443934-B1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101533-A1 | 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC13A3, CLIC1 | CHEK1 1928/4885AURKA 2389/4885DAPK3 4203/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CHEK1 346/4885AURKA 716/4885DAPK3 496/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | CHEK1 1601/4885AURKA 1221/4885DAPK3 1195/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | CHEK1 2788/4885AURKA 1583/4885DAPK3 1432/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | CHEK1 2535/4885AURKA 3432/4885DAPK3 332/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHEK1 1320/4885AURKA 997/4885DAPK3 381/4885 |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | CHEK1 1885/4885AURKA 4521/4885DAPK3 3628/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CHEK1 324/4885AURKA 640/4885DAPK3 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.